サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1404948

オンコロジー臨床試験の市場規模、シェア、動向分析レポート：フェーズタイプ別、研究デザイン別、地域別、セグメント別予測（2023年～2030年）

Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Region, & Segment Forecasts, 2023-2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
オンコロジー臨床試験の市場規模、シェア、動向分析レポート：フェーズタイプ別、研究デザイン別、地域別、セグメント別予測（2023年～2030年）
出版日: 2023年11月10日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オンコロジー臨床試験市場の成長と動向：

世界のオンコロジー臨床試験の市場規模は、2023年～2030年に5.2%のCAGRを記録し、2030年までに194億9,000万米ドルに達すると予測されています。

肺がんは世界中でがん関連死の最大の原因であり、推定180万人が診断され、米国では毎年約6万人が新たに腎細胞がんと診断されていることから、がんと共に生きる人々の数は増加すると予測されています。さらに、がんの有病率の増加と効率的ながん治療に対する需要の増加を反映しています。

連邦政府はオンコロジーの臨床研究に資金を提供し、組織化する上で大きな役割を果たしています。NCIは米国におけるオンコロジー臨床試験のほぼ半分に資金を提供しており、フェーズIIの数が増加しているため、市場成長につながっています。さらに、Medicines Healthcare Products Regulatory Agency（MHRA）によると、2018年～2022年の間に、フェーズIIおよびフェーズIIIの申請は5.5％増加しました。IQVIAは2019年9月にCancer Researchersとの提携を発表し、実データ活用を強化し、オンコロジーの臨床研究を拡大します。

オンコロジー臨床試験市場レポートハイライト

  • フェーズタイプ別では、フェーズIIIセグメントは予測期間中にCAGR5.6%で最速の成長が見込まれます。フェーズIIIのシェアが高いのは、フェーズIIIが最も高額ではありますが、多くの被験者を対象とするためです。フェーズIIIでは、登録および市販後公約のために長期安全性試験が実施されます。
  • 試験デザイン別では、介入試験セグメントは2022年に87.5%と最大の収益シェアを占めました。オンコロジー臨床試験分野における介入試験デザインの促進要因は、主にこれらの疾患特有の課題にあります。
  • 北米は、同地域の製薬および医薬品試験規制が確立されていることから、2022年の売上高シェアは41.8%で市場を独占しました。アジア太平洋は、中国とインドの新興経済圏に未開拓のビジネスチャンスが存在するため、予測期間中にCAGR7.1%の急成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 オンコロジー臨床試験市場の変数と動向

  • 市場力学
    • 市場促進要因の影響分析
    • 市場抑制要因の影響分析
    • 市場機会の影響分析
    • 市場課題の影響分析
  • 業界分析ツール
    • ポーターの分析
    • マクロ経済分析

第4章 オンコロジー臨床試験市場：フェーズタイプ分析

  • フェーズタイプの変動分析と市場シェア（2022年・2030年）
  • フェーズ別
  • フェーズタイプの市場規模と予測、動向分析（2018年～2030年）
    • フェーズI
    • フェーズII
    • フェーズIII
    • フェーズIV

第5章 オンコロジー臨床試験市場：研究デザイン分析

  • 調査デザインの変動分析と市場シェア（2022年・2030年）
  • 研究デザイン別
  • 研究デザインの市場規模と予測、動向分析（2018年～2030年）
    • 介入的
    • 観察的
    • 拡張アクセストライアル

第6章 オンコロジー臨床試験市場：地域の推定・動向分析

  • オンコロジー臨床試験市場：地域の見通し
  • 北米
    • 北米のオンコロジー臨床試験市場の推定と予測（2018年～2030年）
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • デンマーク
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合分析

  • 企業の競合情勢
  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • AstraZeneca
    • Merck & Co., Inc
    • IQVIA Inc
    • Gilead Sciences, Inc
    • F. Hoffmann-La Roche Ltd
    • PAREXEL International Corporation
    • PRA Health Sciences
    • Medpace
    • Pivotal

第8章 アナリストの視点

図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 3 North America oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 4 North America oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 5 U.S. oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 6 U.S. oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 7 Canada oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 8 Canada oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 9 Europe oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 10 Europe oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 11 Europe oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 12 Germany oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 13 Germany oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 14 UK oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 15 UK oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 16 France oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 17 France oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 18 Italy oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 19 Italy oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 20 Spain oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 21 Spain oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 22 Sweden oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 23 Sweden oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 24 Norway oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 25 Norway oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 26 Denmark oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 27 Denmark oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 28 Asia Pacific oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 29 Asia Pacific oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 30 Asia Pacific oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 31 China oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 32 China oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 33 Japan oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 34 Japan oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 35 India oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 36 India oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 37 Australia oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 38 Australia oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 39 Thailand oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 40 Thailand oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 41 South Korea oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 42 South Korea oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 43 Latin America oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 44 Latin America oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 45 Latin America oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 46 Brazil oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 47 Brazil oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 48 Brazil oncology clinical trials market, by application, 2018 - 2030 (USD million)
  • Table 49 Mexico oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 50 Mexico oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 51 Argentina oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 52 Argentina oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 53 Middle East and Africa oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 54 Middle East and Africa oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 55 Middle East and Africa oncology clinical trials market, by region, 2018 - 2030 (USD million)
  • Table 56 South Africa oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 57 South Africa oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 58 Saudi Arabia oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 59 Saudi Arabia oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 60 UAE oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 61 UAE oncology clinical trials market, by study design, 2018 - 2030 (USD million)
  • Table 62 Kuwait oncology clinical trials market, by phase, 2018 - 2030 (USD million)
  • Table 63 Kuwait oncology clinical trials market, by study design, 2018 - 2030 (USD million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Oncology clinical trials: Market outlook
  • Fig. 9 Oncology clinical trials: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Oncology clinical trials market driver impact
  • Fig. 15 Oncology clinical trials market restraint impact
  • Fig. 16 Oncology clinical trials market strategic initiatives analysis
  • Fig. 17 Oncology clinical trials market: Type movement analysis
  • Fig. 18 Oncology clinical trials market: type outlook and key takeaways
  • Fig. 19 Phase I market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Phase II market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Phase III market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Phase IV market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Oncology clinical trials market: study design movement analysis
  • Fig. 25 Oncology clinical trials market: study design outlook and key takeaways
  • Fig. 26 Interventional studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 27 Observational studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 Expanded access studies market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Global oncology clinical trials market: Regional movement analysis
  • Fig. 30 Global oncology clinical trials market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)
目次
Product Code: GVR-4-68039-139-7

Oncology Clinical Trials Market Growth & Trends:

The global oncology clinical trials market size is expected to reach USD 19.49 billion by 2030, registering a CAGR of 5.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. The number of people living with cancer is predicted to rise as lung cancer is the largest cause of cancer-related deaths worldwide, with an estimated 1.8 million people diagnosed and around 60,000 new cases of renal cell carcinoma diagnosed in the U.S. each year. Furthermore, it reflects an increasing prevalence of cancer and an increasing demand for efficient cancer treatment.

The federal government plays a huge role in funding and organizing clinical research in oncology. NCI funds nearly half of all cancer trials in the U.S., and there's a growing number of studies in phase II, leading to market growth. Moreover, according to the Medicines Healthcare Products Regulatory Agency (MHRA), between 2018 and 2022, the application for phase II and phase III trials increased by 5.5%. IQVIA announced a relationship with Cancer Researchers in September 2019 to enhance the use of real-world data and expand clinical research in oncology.

Oncology Clinical Trials Market Report Highlights:

  • Based on phase type, the phase III segment is expected to grow at the fastest CAGR of 5.6% during the forecast period. Phase III segment includes the high share of phase III trials, which is attributed to the fact that phase III trials are the most expensive but involve many subjects. Long-term safety studies are conducted for registration and post-marketing commitments in phase III trials
  • Based on study design, the interventional studies segment accounted for the largest revenue share of 87.5% in 2022. The driving factors for interventional study design in the oncology clinical trials sector primarily revolve around these conditions' unique challenges
  • North America dominated the market with a revenue share of 41.8 % in 2022 owing to the well-established pharmaceutical and drug trials regulations in the region. Asia Pacific is anticipated to grow at the fastest CAGR of 7.1% over the forecast period due to the presence of untapped opportunities in the emerging economies of China and India

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3

Chapter 2 Executive Summary

  • 2.1 Market Outlook
    • 2.1.1 Regional Insights
    • 2.1.2 Competitive Landscape
  • 2.2 Market Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Segment Snapshot
  • 2.5 Competitive Landscape

Chapter 3 Oncology Clinical Trials Market Variables and Trends

  • 3.1 Market Dynamics
    • 3.1.1 Market driver impact analysis
      • 3.1.1.1 Increasing prevalence of Cancer
      • 3.1.1.2 Rise in the number of CROs for conducting research activities
    • 3.1.2 Market restraint impact analysis
      • 3.1.2.1 High cost associated with oncological clinical trial
    • 3.1.3 Market Opportunities impact analysis
      • 3.1.3.1 Technological Advancements
    • 3.1.4 Market challenges impact analysis
      • 3.1.4.1 Strict regulations for patient enrollment in clinical trials
  • 3.2 Industry Analysis Tools
    • 3.2.1 Porter's analysis
    • 3.2.2 Macroeconomic analysis

Chapter 4 Oncology Clinical Trials Market: Phase Type Analysis

  • 4.1 Type Movement Analysis & Market Share, 2022 & 2030
  • 4.2 Oncology Clinical Trials Market Estimates & Forecast, By Phase (USD Million)
  • 4.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Type
    • 4.3.1 Phase I
      • 4.3.1.1 Phase I market, 2018 - 2030 (USD Million)
    • 4.3.2 Phase II
      • 4.3.2.1 Phase II market, 2018 - 2030 (USD Million)
    • 4.3.3 Phase III
      • 4.3.3.1 Phase III market, 2018 - 2030 (USD Million)
    • 4.3.4 Phase IV
      • 4.3.4.1 Phase IV market, 2018 - 2030 (USD Million)

Chapter 5 Oncology Clinical Trials Market: Study Design Analysis

  • 5.1 Study Design Movement Analysis & Market Share, 2022 & 2030
  • 5.2 Oncology Clinical Trials Market Estimates & Forecast, By Study Design (USD Million)
  • 5.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Study Design
    • 5.3.1 Interventional
      • 5.3.1.1 Interventional market, 2018 - 2030 (USD Million)
    • 5.3.2 Observational
      • 5.3.2.1 Observational market, 2018 - 2030 (USD Million)
    • 5.3.3 Expanded access trials
      • 5.3.3.1 Expanded Access market, 2018 - 2030 (USD Million)

Chapter 6 Oncology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 6.1 Oncology Clinical Trials Market: Regional Outlook
  • 6.2 North America
    • 6.2.1 North america oncology clinical trials market estimates & Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 Key country dynamics
      • 6.2.2.2 U.S. oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Key country dynamics
      • 6.2.3.2 Canada oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3 Europe
      • 6.3.1.1 Europe oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 UK
      • 6.3.2.1 Key country dynamics
      • 6.3.2.2 UK oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Key country dynamics
      • 6.3.3.2 Germany oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 Key country dynamics
      • 6.3.4.2 France oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Key country dynamics
      • 6.3.5.2 Italy oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Key country dynamics
      • 6.3.6.2 Spain oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.7 Sweden
      • 6.3.7.1 Key country dynamics
      • 6.3.7.2 Sweden oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.8 Denmark
      • 6.3.8.1 Key country dynamics
      • 6.3.8.2 Denmark oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.9 NORWAY
      • 6.3.9.1 Key country dynamics
      • 6.3.9.2 Norway oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4 ASIA Pacific
      • 6.4.1.1 Asia Pacific oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Key country dynamics
      • 6.4.2.2 Japan oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 Key country dynamics
      • 6.4.3.2 China oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 Key country dynamics
      • 6.4.4.2 India oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5 Australia
      • 6.4.5.1 Key country dynamics
      • 6.4.5.2 Australia oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6 South Korea
      • 6.4.6.1 Key country dynamics
      • 6.4.6.2 South Korea oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7 Thailand
      • 6.4.7.1 Key country dynamics
      • 6.4.7.2 Thailand oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5 Latin America
      • 6.5.1.1 Latin America oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Key country dynamics
      • 6.5.2.2 Brazil oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Key country dynamics
      • 6.5.3.2 Mexico oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Key country dynamics
      • 6.5.4.2 Argentina oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6 Middle East & Africa
      • 6.6.1.1 Middle East & Africa oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 Key country dynamics
      • 6.6.2.2 South Africa oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Key country dynamics
      • 6.6.3.2 Saudi Arabia oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4 UAE
      • 6.6.4.1 Key country dynamics
      • 6.6.4.2 UAE oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5 Kuwait
      • 6.6.5.1 Key country dynamics
      • 6.6.5.2 Kuwait oncology clinical trials market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Company Competitive Landscape
  • 7.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2 Market Participant Categorization
    • 7.2.1 AstraZeneca
      • 7.2.1.1 Company overview
      • 7.2.1.2 Financial performance
      • 7.2.1.3 Phase benchmarking
      • 7.2.1.4 Strategic initiatives
    • 7.2.2 Merck & Co., Inc
      • 7.2.2.1 Company overview
      • 7.2.2.2 Financial performance
      • 7.2.2.3 Phase benchmarking
      • 7.2.2.4 Strategic initiatives
    • 7.2.3 IQVIA Inc
      • 7.2.3.1 Company overview
      • 7.2.3.2 Financial performance
      • 7.2.3.3 Phase benchmarking
      • 7.2.3.4 Strategic initiatives
    • 7.2.4 Gilead Sciences, Inc
      • 7.2.4.1 Company overview
      • 7.2.4.2 Financial performance
      • 7.2.4.3 Phase benchmarking
      • 7.2.4.4 Strategic initiatives
    • 7.2.5 F. Hoffmann-La Roche Ltd
      • 7.2.5.1 Company overview
      • 7.2.5.2 Financial performance
      • 7.2.5.3 Phase benchmarking
      • 7.2.5.4 Strategic initiatives
    • 7.2.6 PAREXEL International Corporation
      • 7.2.6.1 Company overview
      • 7.2.6.2 Financial performance
      • 7.2.6.3 Phase benchmarking
      • 7.2.6.4 Strategic initiatives
    • 7.2.7 PRA Health Sciences
      • 7.2.7.1 Company overview
      • 7.2.7.2 Financial performance
      • 7.2.7.3 Phase benchmarking
      • 7.2.7.4 Strategic initiatives
    • 7.2.8 Medpace
      • 7.2.8.1 Company overview
      • 7.2.8.2 Financial performance
      • 7.2.8.3 Phase benchmarking
      • 7.2.8.4 Strategic initiatives
    • 7.2.9 Pivotal
      • 7.2.9.1 Company overview
      • 7.2.9.2 Financial performance
      • 7.2.9.3 Phase benchmarking
      • 7.2.9.4 Strategic initiatives

Chapter 8 Analyst Perspective